Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 4/20 | 0.76 |
| ▸ | DOT1L | Q8TEK3 | 5/20 | 0.75 |
| ▸ | EHMT2 | Q96KQ7 | 4/20 | 0.75 |
| ▸ | CARM1 | Q86X55 | 4/20 | 0.75 |
| ▸ | NSD2 | O96028 | 3/20 | 0.75 |
| ▸ | SETD7 | Q8WTS6 | 3/20 | 0.75 |
| ▸ | PCMT1 | P22061 | 2/20 | 0.75 |
| ▸ | TRDMT1 | O14717 | 2/20 | 0.75 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.75 |
| ▸ | INMT | O95050 | 2/20 | 0.75 |
| ▸ | METTL3 | Q86U44 | 2/20 | 0.75 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.75 |
| ▸ | EHMT1 | Q9H9B1 | 2/20 | 0.75 |
| ▸ | METTL14 | Q9HCE5 | 2/20 | 0.75 |
| ▸ | RNMT | O43148 | 1/20 | 0.75 |
| ▸ | TPMT | P51580 | 1/20 | 0.75 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.75 |
| ▸ | SETD2 | Q9BYW2 | 1/20 | 0.75 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.75 |
| ▸ | FASN | P49327 | 3/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17079889 | 1.00 | NNMT (0.76) | NNMTDOT1LEHMT2CARM1NSD2 | |
| SCHEMBL27092943 | 1.00 | NNMT (0.76) | NNMTDOT1LEHMT2CARM1NSD2 | |
| SCHEMBL28157647 | 1.00 | NNMT (0.76) | NNMTDOT1LEHMT2CARM1NSD2 | |
| SCHEMBL27092948 | 1.00 | NNMT (0.76) | NNMTDOT1LEHMT2CARM1NSD2 | |
| SCHEMBL27092952 | 0.91 | NNMT (0.64) | NNMTDOT1LEHMT2CARM1NSD2 | |
| SCHEMBL27092945 | 0.91 | NNMT (0.64) | NNMTDOT1LEHMT2CARM1NSD2 | |
| SCHEMBL27092986 | 0.91 | EHMT2 (0.71) | NNMTDOT1LEHMT2CARM1NSD2 | |
| SCHEMBL27092981 | 0.91 | EHMT2 (0.71) | NNMTDOT1LEHMT2CARM1NSD2 | |
| SCHEMBL27092930 | 0.90 | NNMT (0.62) | NNMTDOT1LEHMT2CARM1NSD2 | |
| SCHEMBL27092937 | 0.90 | NNMT (0.62) | NNMTDOT1LEHMT2CARM1NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11613552-B2 | Pharmaceutical agents, compositions, and methods relating thereto | ALLTECH, INC. (US) | 2023-03-28 | — | — | US | disclosed |
| EP-3144001-B1 | COMPOSITIONS OF SELENOORGANIC COMPOUNDS AND METHODS OF USE THEREOF | ALLTECH INC (US) | 2021-08-11 | — | — | EP | disclosed |
| US-20210238216-A1 | PHARMACEUTICAL AGENTS, COMPOSITIONS, AND METHODS RELATING THERETO | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT | 2021-08-05 | — | — | US | disclosed |
| US-11014954-B2 | Pharmaceutical agents, compositions, and methods relating thereto | ALLTECH, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| EP-3116511-B1 | COMPOSITIONS OF SELENOORGANIC COMPOUNDS AND METHODS OF USE THEREOF | ALLTECH INC (US) | 2020-08-26 | — | — | EP | disclosed |
| US-20200123191-A1 | PHARMACEUTICAL AGENTS, COMPOSITIONS, AND METHODS RELATING THERETO | ALLTECH, INC. (US) | 2020-04-23 | — | — | US | disclosed |
| EP-3624809-A1 | PHARMACEUTICAL AGENTS, COMPOSITIONS, AND METHODS RELATING THERETO | Alltech, Inc. (US) | 2020-03-25 | — | — | EP | disclosed |
| US-10201559-B2 | Compositions of selenoorganic compounds and methods of use thereof | ALLTECH, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-10201558-B2 | Compositions of selenoorganic compounds and methods of use thereof | ALLTECH, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| WO-2018212980-A1 | PHARMACEUTICAL AGENTS, COMPOSITIONS, AND METHODS RELATING THERETO | ALLTECH, INC. (US) | 2018-11-22 | — | — | WO | disclosed |
| WO-2017048253-A1 | COMPOSITIONS OF SELENOORGANIC COMPOUNDS AND METHODS OF USE THEREOF | ALLTECH, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| WO-2017048252-A1 | COMPOSITIONS OF SELENOORGANIC COMPOUNDS AND METHODS OF USE THEREOF | ALLTECH, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| EP-3144001-A1 | COMPOSITIONS OF SELENOORGANIC COMPOUNDS AND METHODS OF USE THEREOF | Alltech, Inc. (US) | 2017-03-22 | — | — | EP | disclosed |
| EP-3116511-A1 | COMPOSITIONS OF SELENOORGANIC COMPOUNDS AND METHODS OF USE THEREOF | Alltech, Inc. (US) | 2017-01-18 | — | — | EP | disclosed |
| US-20160361338-A1 | COMPOSITIONS OF SELENOORGANIC COMPOUNDS AND METHODS OF USE THEREOF | ALLTECH, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160082033-A1 | COMPOSITIONS OF SELENOORGANIC COMPOUNDS AND METHODS OF USE THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT | 2016-03-24 | — | — | US | disclosed |
| US-20160045533-A1 | COMPOSITIONS OF SELENOORGANIC COMPOUNDS AND METHODS OF USE THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT | 2016-02-18 | — | — | US | disclosed |
| WO-2015137983-A1 | COMPOSITIONS OF SELENOORGANIC COMPOUNDS AND METHODS OF USE THEREOF | ALLTECH, INC. (US) | 2015-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160045533-A1 | COMPOSITIONS OF SELENOORGANIC COMPOUNDS AND METHODS OF USE THEREOF | SCLY, BHMT2, CBS | NNMT 80/4885DOT1L 2083/4885EHMT2 354/4885 |
| US-10201559-B2 | Compositions of selenoorganic compounds and methods of use thereof | SHMT2, FPGS, MTR | NNMT 234/4885DOT1L 2491/4885EHMT2 446/4885 |
| US-20160361338-A1 | COMPOSITIONS OF SELENOORGANIC COMPOUNDS AND METHODS OF USE THEREOF | SHMT2, FPGS, MTR | NNMT 234/4885DOT1L 2491/4885EHMT2 446/4885 |
| US-20210238216-A1 | PHARMACEUTICAL AGENTS, COMPOSITIONS, AND METHODS RELATING THERETO | PCSK9, PCSK7, PDE3A | NNMT 3918/4885DOT1L 4783/4885EHMT2 4826/4885 |
| US-11014954-B2 | Pharmaceutical agents, compositions, and methods relating thereto | PCSK9, PCSK7, PDE3A | NNMT 3918/4885DOT1L 4783/4885EHMT2 4826/4885 |
| US-20160082033-A1 | COMPOSITIONS OF SELENOORGANIC COMPOUNDS AND METHODS OF USE THEREOF | PSEN2, PSEN1, BACE1 | NNMT 32/4885DOT1L 3832/4885EHMT2 1847/4885 |
| US-11613552-B2 | Pharmaceutical agents, compositions, and methods relating thereto | PCSK9, PCSK7, PDE3A | NNMT 3918/4885DOT1L 4783/4885EHMT2 4826/4885 |
| US-10201558-B2 | Compositions of selenoorganic compounds and methods of use thereof | PSEN2, PSEN1, BACE1 | NNMT 32/4885DOT1L 3832/4885EHMT2 1847/4885 |
| US-20200123191-A1 | PHARMACEUTICAL AGENTS, COMPOSITIONS, AND METHODS RELATING THERETO | PCSK9, PCSK7, PDE3A | NNMT 3918/4885DOT1L 4783/4885EHMT2 4826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.